Phenylbutazone kinetics and metabolite concentrations in the horse after five days of administration.

This study evaluates the kinetics and metabolite concentrations of phenylbutazone, a non-steroidal anti-inflammatory drug, in horses after it is administered for five consecutive days, both orally and intravenously.

Methodology and Procedure

• The researchers conducted a study where phenylbutazone was administered to horses at a specific dosage (8.8 mg/kg of body weight), daily for five consecutive days.
• The medication was given orally for the first four days, and on the fifth day it was administered through an intravenous (IV) injection.

Key Findings and Results

• The half-life of phenylbutazone following this regimen was discovered to be approximately 6.2 hours, with the volume of distribution being 0.152 +/- 0.014 L/kg. Simply put, the time taken for the drug concentration to reduce by half in the body was 6.2 hours.
• The drug’s bioavailability, or the degree and rate at which it is absorbed into the body’s circulatory system, was found to be around 91.8 +/- 2.5% after oral administration.
• Research showed a steady increase in plasma concentration of phenylbutazone from the first day to the second and then levelling off after the second day. This meant that the body was absorbing the drug efficiently and steadily until the second day, after which it maintained a steady state.
• There were no observed changes in the urinary concentrations of the drug during the 5-day dosing period, indicating that the drug’s elimination through urine remained consistent over the study period.
• However, the researchers observed increases in the metabolites of phenylbutazone, specifically oxyphenbutazone and the alpha-alcohol, during the five-day dosing period. A metabolite is a product of the body’s metabolism process, essentially a substance produced when the body processes a drug.
• There was a noted delay in the appearance of the alpha-alcohol metabolite in urine following both oral and IV administration of phenylbutazone. This could suggest that the body’s processing and elimination of this particular metabolite happened at a slower rate.

Significance of the Research

• This study is significant as it provides useful insights about how the body metabolizes and processes phenylbutazone in horses, a commonly used non-steroidal anti-inflammatory drug.
• With the knowledge obtained from this study, healthcare practitioners can better understand the drug’s pharmacokinetics and accordingly adjust the dosing and administration methods to achieve optimal therapeutic effects.